The Transform Trial is a multi-million pound project designed to change how aggressive prostate cancer is detected at the earliest stage – a goal we all share. 

About the Trial 

Recruitment will be GP-led, starting with 10,000–12,000 men over 2–3 years, with the aim of expanding to 200,000–300,000 men nationwide. 

Participants will be split into two groups: 

• Testing group: A mix of approaches, including PSA alone, PSA with MRI, MRI alone, advanced PSA tests, and potentially genetic testing. PSA levels will vary across groups. 
• Control group: No testing interventions. 

Full trial details are expected to be published soon. 

Contamination

A major challenge is “contamination,” where participants who already had tests may skew results. Any man who has had a PSA test in the last 5 years will be excluded. 

This includes tests done via: 

• GP appointments
• Workplace health checks
• BUPA or private medicals
• Home testing kits
• GFCT testing events

It is vital that invited men check carefully whether they’ve had a PSA test in the last five years before enrolling. 

Please Share & Support 

This is a landmark project with the potential to shape the future of prostate cancer screening. Please share this update so others are aware and can ensure eligibility. 

Learn more about Transform - https://tgfct.org.uk/Research/TRANSFORM 

GFCT Treatment Support 

Alongside testing, GFCT also supports treatment. GFCT Treatment Support was created after discussions with Professor Hashim Ahmed (Imperial College), who highlighted the urgent need for HIFU (High-Intensity Focused Ultrasound) equipment in hospitals taking part in the Transform trial. 

Our mission is to raise funds for prostate cancer diagnosis and treatment technology, including HIFU machines, to support the NHS and ensure men have access to the best care. 

Learn more about GFCT Treatment Support: https://gfcttreatmentsupport.co.uk